UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/663,693	09/17/2003	Evgenu Nudler	NUDLER2A	3974
1444 BROWDY AN	EXAM	IINER		
624 NINTH STREET, NW SUITE 300 WASHINGTON, DC 20001-5303			SACKEY, EBENEZER O	
			ART UNIT	PAPER NUMBER
			1624	
			MAIL DATE	DELIVERY MODE
			06/06/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	_		
	10/663,693	NUDLER ET AL.			
Office Action Summary	Examiner	Art Unit			
	EBENEZER SACKEY	1624			
The MAILING DATE of this communication Period for Reply	appears on the cover sheet wit	h the correspondence address			
A SHORTENED STATUTORY PERIOD FOR REWHICHEVER IS LONGER, FROM THE MAILING. - Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory provided to reply within the set or extended period for reply will, by some Any reply received by the Office later than three months after the rearned patent term adjustment. See 37 CFR 1.704(b).	G DATE OF THIS COMMUNIC FR 1.136(a). In no event, however, may a re n. eriod will apply and will expire SIX (6) MONT statute, cause the application to become ABA	ATION. ply be timely filed HS from the mailing date of this communication. INDONED (35 U.S.C. § 133).			
Status					
 Responsive to communication(s) filed on 1 This action is FINAL. 2b) Since this application is in condition for all closed in accordance with the practice under the closed. 	This action is non-final. owance except for formal matte	·			
Disposition of Claims					
4) ☐ Claim(s) 1-7,9-26 and 28 is/are pending in 4a) Of the above claim(s) 15-20 and 23 is/a 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-7,9-14,21,22 and 24-26 is/are r 7) ☐ Claim(s) 28 is/are objected to. 8) ☐ Claim(s) are subject to restriction as	are withdrawn from consideration rejected. nd/or election requirement.	on.			
 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	B) Paper No(s)	ummary (PTO-413) /Mail Date formal Patent Application -			

DETAILED ACTION

Status of the Claims

Claims 1-7, 9-26 and 28 are pending.

This is in response to applicant's amendment filed on 03/19/08.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 03/19/08 has been entered.

Claim Objections

Claim 1 is objected to because of the following informalities: spelling error on line 3, "thereof" has been spelled as ----there of----. Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The rejection of claims 1-14, 21-22, 24-26 and 28 under 35 U.S.C 112, first paragraph has been withdrawn.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-7, 9-14, 21-22 and 24-26 remain rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention for the reasons set forth in the previous office action mailed on 09/19/07.

Response to Remarks

Applicant's arguments filed 01/18/08 have been fully considered but they are not deemed persuasive. Applicants argue that the term "perfluorocarbon" is well-known in the art. Applicants have also submitted various articles to support the notion that the term "perfluorocarbon" is a term frequently used in Medicine and thus, known to those skilled in the art.

With regard to the plethora of intended uses recited in currently amended claim 1, the various uses render the claim ambiguous since there is no evidence of record to correlate the connection between the various diseases and the metabolism of nitric oxide.

It is not conceivable that the dosage regimen for uses as varied as hypertension v. angina or arthritis or hair loss or impotence would all be the same and there is no evidence in the specification pointing to a particular regimen for the many uses recited. Additionally, it is not clear what constitutes a HELP syndrome because a syndrome is usually a complex of symptoms (none present) indicating the existence of an

Art Unit: 1624

undesirable condition. With respect to the treatment of Alzheimer's disease (a very difficult disease to treat) by metabolism nitric oxide, no such correlation has been presented or forth coming. It is believed that Alzheimer's happens because of changes in neurotransmitters not metabolism of nitric oxide.

Making the publications recited on page 10 of applicant's remarks of record may help to determine the relationship between metabolism of nitric oxide and the various diseases recited.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to E. Sackey whose telephone number is (571) 272-0704. The examiner can normally be reached on Monday-Friday from 7:30 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson, can be reached on (571) 272-0661. The fax phone number for this Group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

EOS

/James O. Wilson/

Supervisory Patent Examiner, Art Unit 1624

Application/Control Number: 10/663,693 Page 5

Art Unit: 1624

Application Number

Application/Control No.	Applicant(s)/Patent under Reexamination
10/663,693	NUDLER ET AL.
Examiner	Art Unit
ERENEZER SACKEV	1624